ThromboGenics Ltd. to Absorb Subsidiary Thromb-X, NV

May 23, 2007 |

1 min read

BRUSSELS (Thomson Financial) - Belgian biotechnology company ThromboGenics NV said it plans to absorb its subsidiary Thromb-X. The company said the transaction will issue no new shares or cash payment.

Mergers & acquisitions Europe

MORE ON THIS TOPIC

Big fish eats small, takeover of the company. Art collage.

Mergers & acquisitions

Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms

March 25, 2026

·

3 min read

·

Tristan Manalac

A train with blue background, 3d rendering. Computer digital drawing.

Mergers & acquisitions

Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos

March 24, 2026

·

3 min read

·

Tristan Manalac

Illustration showing a handshake, signaling cooperation, goodwill

Immunology and inflammation

Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+

March 23, 2026

·

2 min read

·

Tristan Manalac

Hand collage holding dollar paper money isolated on yellow background. Using cash to buy concept. Halftone effect in pop art style illustration.

Breast cancer

Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals

March 20, 2026

·

2 min read

·

Tristan Manalac